AR023848A1 - Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico - Google Patents

Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico

Info

Publication number
AR023848A1
AR023848A1 ARP000102136A ARP000102136A AR023848A1 AR 023848 A1 AR023848 A1 AR 023848A1 AR P000102136 A ARP000102136 A AR P000102136A AR P000102136 A ARP000102136 A AR P000102136A AR 023848 A1 AR023848 A1 AR 023848A1
Authority
AR
Argentina
Prior art keywords
gpvi
recombinant
disorders
glicoprotein
plates
Prior art date
Application number
ARP000102136A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR023848(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR023848A1 publication Critical patent/AR023848A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/018—Platelets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)

Abstract

Glicoporteína VI (GPVI), su aislamiento, purificacion y métodos para la produccion recombinante. En especial, la invencion se relaciona con el uso de laGPVI, preferentemente GPVI recombinante, en el tratamientos de desordenes y eventos patologicos correlacionados directa o indirectamente con desordenes de lacoagulacion de la sangre tales como desordenes tromboticos y cardiovasculares. La proteína recombinante extracelular también se puede usar para establecerensayos de rastreo (screening) para encontrar potenciales inhibidores de la GPVI unida a membrana para inhibir la union al colágeno de trombocitos y plaquetas,respectivamente. Se pueden usar cambios en la GPVI para monitorear la edad de las plaquetas y la exposicion a enfermedades tromboticas y cardiovasculares.
ARP000102136A 1999-05-07 2000-05-04 Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico AR023848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99109094 1999-05-07

Publications (1)

Publication Number Publication Date
AR023848A1 true AR023848A1 (es) 2002-09-04

Family

ID=8238132

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102136A AR023848A1 (es) 1999-05-07 2000-05-04 Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico

Country Status (26)

Country Link
US (5) US7928066B1 (es)
EP (3) EP2341141B1 (es)
JP (2) JP5480457B2 (es)
KR (1) KR100703592B1 (es)
CN (1) CN1253569C (es)
AR (1) AR023848A1 (es)
AT (1) ATE393223T1 (es)
AU (1) AU775952B2 (es)
BR (1) BRPI0010325B1 (es)
CA (1) CA2372515C (es)
CY (2) CY1108190T1 (es)
CZ (1) CZ302693B6 (es)
DE (1) DE60038675T2 (es)
DK (2) DK2341141T3 (es)
ES (2) ES2534652T3 (es)
HK (1) HK1045714B (es)
HU (1) HUP0201049A2 (es)
MX (1) MXPA01011274A (es)
NO (1) NO333408B1 (es)
PL (1) PL204449B1 (es)
PT (2) PT1177289E (es)
RU (1) RU2287580C2 (es)
SI (1) SI1177289T1 (es)
SK (1) SK15762001A3 (es)
WO (1) WO2000068377A1 (es)
ZA (1) ZA200110071B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2287580C2 (ru) 1999-05-07 2006-11-20 Авентис Фарма Дойчланд Гмбх Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин vi и его применение в фармацевтике
US6245527B1 (en) 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) * 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
AU2002333241B2 (en) * 2001-07-18 2008-09-18 Merck Patent Gmbh Glycoprotein VI fusion proteins
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
DE102004017295A1 (de) * 2004-04-05 2005-11-03 Zlb Behring Gmbh Verbindungen, welche die Entfernung von Rezeptoren von Zelllmembranen bewirken oder verhindern, und Verfahren zu ihrem Nachweis
WO2005111083A2 (en) 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein vi and methods of producing these antibodies
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
US20100297116A1 (en) * 2007-10-31 2010-11-25 Yongge Liu Uses of a glycoprotein vi (gpvi) inhibitor
EP3150750B1 (en) 2011-04-08 2018-12-26 Prognosys Biosciences, Inc. Peptide constructs and assay systems
EP3184544A1 (en) * 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143416C (en) 1993-07-01 2003-06-10 Jurgen Hemberger Inhibitor of collagen-stimulated platelet aggregation
NZ275492A (en) * 1993-10-22 1998-05-27 Ellerman Pharm Ltd Peptide analogues of platelet-derived growth factor
WO1998031806A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Fc RECEPTORS AND POLYPEPTIDES
EP0896002A4 (en) * 1997-01-29 2005-02-02 Toray Industries CHIMERIC PROTEINS, THEIR HETERODIMER COMPLEXES AND BLOOD PLATE REPLACEMENT
RU2287580C2 (ru) 1999-05-07 2006-11-20 Авентис Фарма Дойчланд Гмбх Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин vi и его применение в фармацевтике
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
WO2001016321A1 (en) * 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
AU2002333241B2 (en) 2001-07-18 2008-09-18 Merck Patent Gmbh Glycoprotein VI fusion proteins
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4

Also Published As

Publication number Publication date
PT2341141E (pt) 2015-04-30
BRPI0010325B1 (pt) 2016-01-19
EP2341141A2 (en) 2011-07-06
NO20015420L (no) 2002-01-03
CA2372515C (en) 2015-12-01
EP2341141B1 (en) 2015-01-14
EP1942186A2 (en) 2008-07-09
BR0010325A (pt) 2002-02-26
JP2003515313A (ja) 2003-05-07
SI1177289T1 (sl) 2008-08-31
EP2341141A3 (en) 2012-03-28
EP1942186B1 (en) 2017-04-12
CY1116336T1 (el) 2017-02-08
ES2304347T3 (es) 2008-10-16
RU2287580C2 (ru) 2006-11-20
ES2534652T3 (es) 2015-04-27
US7928066B1 (en) 2011-04-19
US20070172893A1 (en) 2007-07-26
PL204449B1 (pl) 2010-01-29
PL351437A1 (en) 2003-04-22
CN1350583A (zh) 2002-05-22
DE60038675T2 (de) 2009-07-02
JP5480457B2 (ja) 2014-04-23
DK1177289T3 (da) 2008-08-11
US20110237655A1 (en) 2011-09-29
CZ20013989A3 (cs) 2002-02-13
US8198030B2 (en) 2012-06-12
EP1177289B1 (en) 2008-04-23
CY1108190T1 (el) 2014-02-12
CN1253569C (zh) 2006-04-26
SK15762001A3 (sk) 2002-04-04
ATE393223T1 (de) 2008-05-15
CA2372515A1 (en) 2000-11-16
KR100703592B1 (ko) 2007-04-05
US20160207976A1 (en) 2016-07-21
ZA200110071B (en) 2003-03-06
EP1177289A1 (en) 2002-02-06
AU4555500A (en) 2000-11-21
WO2000068377A1 (en) 2000-11-16
PT1177289E (pt) 2008-06-30
CZ302693B6 (cs) 2011-09-07
MXPA01011274A (es) 2002-05-06
HK1045714B (zh) 2006-09-22
HK1045714A1 (en) 2002-12-06
EP1942186A3 (en) 2008-10-08
NO333408B1 (no) 2013-05-27
US20070172480A1 (en) 2007-07-26
HUP0201049A2 (hu) 2002-07-29
DE60038675D1 (de) 2008-06-05
JP5554696B2 (ja) 2014-07-23
US8278430B2 (en) 2012-10-02
JP2011097948A (ja) 2011-05-19
KR20010112951A (ko) 2001-12-22
AU775952B2 (en) 2004-08-19
DK2341141T3 (en) 2015-04-20
NO20015420D0 (no) 2001-11-06

Similar Documents

Publication Publication Date Title
AR023848A1 (es) Glicoproteina vi recombinante del receptor de colageno sobre plaquetas y su uso farmaceutico
BRPI0506537A (pt) compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
CR8131A (es) Peptidos novedosos que se unen al receptor de la eritropoyetina
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
ECSP088262A (es) Proteínas de fusión de albúmina
ECSP088508A (es) Antagonistas de neuropilina
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
TR200100149T2 (tr) Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
Belotti et al. Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFβ and in cooperation with PDGF
ES2151880T3 (es) Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.
DE69434332D1 (de) Thrombin mutanten
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
WO2005046570A3 (en) Human stem cell materials and methods
SV2009002997A (es) Modulacion de la formacion osea
MA29439B1 (fr) Derives d'uree d'heteroaryle utilises pour inhiber chk1
MA31454B1 (fr) Modulateurs de la kallikreine 7
PT811001E (pt) Dioxidos de benzotiazina como antagonistas de endotelina
DE602005017812D1 (de) Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit
CO2022010337A2 (es) Anticuerpos monoclonales anti-sirpα y usos de los mismos
AR023546A1 (es) Disulfuros ciclicos de pirrolidincarbonilamina
AR039803A1 (es) Proteinas 1 y 2 relacionadas con el receptor ldl y tratamiento de los trastornos de huesos o cartilago
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
GT200500370A (es) Nuevos usos para los agonistas beta de estrogeno
ES2120506T3 (es) Nuevas amidas, sulfonamidas y sulfonamidas de piperidilo utilizadas como inhibidores de la biosintesis del colesterol.

Legal Events

Date Code Title Description
FB Suspension of granting procedure